Nephrotoxic Potential of Bence Jones Proteins

New England Journal of Medicine

Volumn 324, Issue 26, 1991, Pages 1845-1851

  Solomon, Alan ^a   Weiss, Deborah T ^a   Kattine, Anthony A ^b  

^a Graduate Schook of Medicine ^*  (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BENCE JONES PROTEIN; CREATININE; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULINS, LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ANIMAL; ARTICLE; BLOOD; CRYSTALLIZATION; FEMALE; HUMAN; KIDNEY; KIDNEY DISEASE; MALE; METABOLISM; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID; AMYLOIDOSIS; ANIMAL; BENCE JONES PROTEIN; CREATININE; CRYSTALLIZATION; FEMALE; HUMAN; IMMUNOGLOBULINS, LIGHT-CHAIN; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C3H; MIDDLE AGE; MULTIPLE MYELOMA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026432631     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199106273242603     Document Type: Article

References (41)

1. Solomon A. Clinical implications of monoclonal light chains. Semin Oncol 1986; 13: 341–9.
2. Hill GS. Multiple myeloma, amyloidosis, Waldenström's macroglobulinemia, cryoglobulinemias, and benign monoclonal gammopathies. In: Heptinstall RH, ed. Pathology of the kidney. Vol. 2. Boston: Little, Brown, 1983:993–1067.
3. Gallo GR, Feiner HD, Buxbaum JN. The kidney in lymphoplasmacytic disorders. Pathol Annu 1982; 17: 291–317.
4. Pirani CL, Silva FG, Appel GB. Tubulo-interstitial disease in multiple myeloma and other nonrenal neoplasias. In: Cotran RS, ed. Tubulo-interstitial nephropathies. Vol. 10 of Contemporary issues in nephrology. New York: Churchill-Livingstone, 1982:287–335.
5. Glenner GG. Amyloid deposits and amyloidosis: the β-fibrilloses. N Engl J Med 1980; 302: 1283–92, 1333–43.
6. Fang LST. Light-chain nephropathy. Kidney Int 1985; 27: 582–92.
7. Sturgill BC, Tucker FL, Bolton WK. Immunoglobulin light chain nephropathies. Pathol Annu 1987; 22: 133–50.
8. Kyle RA. Monoclonal gammopathies and the kidney. Annu Rev Med 1989; 40: 53–60.
9. Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987; 66: 126–37.
10. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma: plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150: 863–9.
11. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–5.
12. Clyne DH, Pesce AJ, Thompson RE. Nephrotoxicity of Bence Jones proteins in the rat: importance of protein isoelectric point. Kidney Int 1979; 16: 345–52.
13. Preud'homme JL, Morel-Maroger L, Brouet JC, et al. Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition. Am J Med 1980; 69: 703–10.
14. Weiss JH, Williams RH, Galla JH, et al. Pathophysiology of acute Bencex-Jones protein nephrotoxicity in the rat. Kidney Int 1981; 20: 198–210.
15. Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins: preferential association of the VλVI subgroup of human light chains with amyloidosis AL (λ). J Clin Invest 1982; 70: 453–60.
16. Hill GS, Morel-Maroger L, Méry J-P, Brouet JC, Mignon F. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis 1983; 2: 423–38.
17. Smolens P, Venkatachalam M, Stein JH. Myeloma kidney cast nephropathy in a rat model of multiple myeloma. Kidney Int 1983; 24: 192–204.
18. Coward RA, Delamore IW, Mallick NP, Robinson EL. The importance of urinary immunoglobulin light chain isoelectric point (pI) in nephrotoxicity in multiple myeloma. Clin Sci 1984; 66: 229–32.
19. Sølling K, Sølling J, Lanng-Nielsen J. Polymeric Bence Jones proteins in serum in myeloma patients with renal insufficiency. Acta Med Scand 1984; 216: 495–502.
20. Palant CE, Bonitati J, Bartholomew WR, Brentjens JR, Walshe JJ, Bentzel CJ. Nodular glomerulosclerosis associated with multiple myeloma: role of light chain isoelectric point. Am J Med 1986; 80: 98–102.
21. Buxbaum J. Aberrant immunoglobulin synthesis in light chain amyloidosis: free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. J Clin Invest 1986; 78: 798–806.
22. Smolens P, Barnes JL, Stein JH. Effect of chronic administration of different Bence Jones proteins on rat kidney. Kidney Int 1986; 30: 874–82.
23. Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988; 82: 2086–96.
24. Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990; 85: 570–6.
25. Solomon A. Bence Jones proteins: malignant or benign? N Engl J Med 1982; 306: 605–7.
26. Koss MN, Pirani CL, Osserman EF. Experimental Bence Jones cast nephropathy. Lab Invest 1976; 34: 579–91.
27. Clyne DH, Pollak VE. Renal handling and pathophysiology of Bence Jones proteins. Contrib Nephrol 1981; 24: 78–87.
28. Sanders PW, Herrera GA, Galla JH. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987; 32: 851–61.
29. Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967; 126: 207–21.
30. Solomon A. Light chains of human immunoglobulins. In: Di Sabato G, Langone JJ, Van Vunakis H, eds. Immunochemical techniques. Part H: effectors and mediators of lymphoid cell functions. Vol. 116 of Methods in enzymology. Orlando, Fla.: Academic Press, 1985:101–21.
31. Solomon A, McLaughlin CL, Capra JD. Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy. J Clin Invest 1975; 55: 579–86.
32. Solomon A, Weiss DT, Macy SD, Antonucci RA. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies. Am J Pathol 1990; 137: 855–62.
33. Gallo G, Picken M, Buxbaum J, Frangione B. The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias. Semin Hematol 1989; 26: 234–45.
34. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJS. Manifestations of systemic light chain deposition. Am J Med 1976; 60: 293–9.
35. Ganeval D, Noël L-H, Preud'homme J-L, Droz D, Grünfeld J-P. Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int 1984; 26: 1–9.
36. Tubbs RR, Gephardt GN, McMahon JT, Hall PM, Valenzuela R, Vidt DG. Light chain nephropathy. Am J Med 1981; 71: 263–9.
37. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Ann Intern Med 1990; 112: 455–64.
38. Melcion C, Mougenot B, Baudouin B, et al. Renal failure in myeloma: relationship with isoelectric point of immunoglobulin light chains. Clin Nephrol 1984; 22: 138–43.
39. Cooper EH, Forbes MA, Crockson RA, MacLennan ICM. Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. J Clin Pathol 1984; 37: 852–8.
40. Johns EA, Turner R, Cooper EH, MacLennan ICM. Isoelectric points of urinary light chains in myelomatosis: analysis in relation to nephrotoxicity. J Clin Pathol 1986; 39: 833–7.
41. Norden AGW, Flynn FV, Filcher LM, Richards JDM. Renal impairment in myeloma: negative association with isoelectric point of excreted Bence-Jones protein. J Clin Pathol 1989; 42: 59–62.